A drug that suppresses cancer cell division more effectively than what doctors have been using
At a European oncology congress this week, researchers presented early evidence that giredestrant, a new oral hormone therapy, suppresses tumor growth markers more effectively than the long-standing standard treatment for the most common form of breast cancer. The finding carries quiet weight for the hundreds of thousands of women diagnosed each year with estrogen-receptor-positive disease — and particular urgency for the half who will eventually find that existing drugs no longer hold their cancer at bay. Science rarely offers sudden reversals of fortune, but occasionally it offers a more promising door, and this study suggests one may be worth opening.
- Up to 100,000 women annually develop resistance to current hormone therapies, leaving them with narrowing options as their tumors continue to grow.
- In a head-to-head comparison, giredestrant reduced a key marker of cancer cell division by 80% in just two weeks — outpacing the standard drug anastrozole's 67% reduction by a margin oncologists consider meaningful.
- The drug belongs to a new class of oral therapies that work by degrading estrogen receptors entirely, potentially overcoming the resistance mechanisms that render older treatments ineffective.
- Researchers caution that this is early-stage data from 191 patients, and larger randomized trials are needed before the drug's effect on long-term survival and recurrence can be confirmed.
- The study's lead author has called the results solid enough rationale to advance trials in both early-stage and metastatic settings, signaling cautious but genuine momentum in the field.
At a medical conference in Europe this week, researchers shared findings that a new pill-based hormone therapy called giredestrant outperforms the standard treatment for the most common subtype of breast cancer — a result that carries real stakes for tens of thousands of women each year.
The study enrolled 191 post-menopausal women with early-stage, estrogen-receptor-positive breast cancer. Half received two weeks of giredestrant; the other half received anastrozole, the long-established standard. Tumor biopsies taken afterward revealed a telling difference: patients on giredestrant showed an 80% drop in Ki67, a protein that signals how rapidly cancer cells are dividing, compared to a 67% reduction in those given anastrozole. In oncology, that gap suggests a drug working more forcefully against the machinery of tumor growth.
Giredestrant belongs to a new class of therapies called selective estrogen receptor degraders. Unlike most existing hormone treatments, it comes as a pill and works by dismantling the receptors that draw estrogen toward tumors — starving them of the fuel they need. This mechanism may prove especially valuable for women whose cancers have become resistant to conventional drugs, a problem that affects roughly half of the 200,000 women diagnosed with this cancer subtype in the United States each year.
Dr. Sara Hurvitz of UCLA's Jonsson Comprehensive Cancer Center, who co-authored the study, noted that sharp early drops in Ki67 have historically been associated with better long-term outcomes and lower recurrence rates — a connection that lends the new findings added significance, even if survival benefit remains to be proven. Larger randomized trials are now planned to determine whether this early promise translates into something patients and physicians can truly count on.
At a medical conference in Europe this week, researchers presented evidence that a new pill-based hormone therapy called giredestrant outperforms the standard treatment for a particularly common form of breast cancer. The finding matters because it offers a potential path forward for women whose tumors have grown resistant to existing drugs—a problem that affects tens of thousands of patients each year.
The study involved 191 post-menopausal women with early-stage, estrogen-receptor-positive breast cancer that had not yet spread. Half received two weeks of giredestrant; the other half received the same duration of anastrozole, a hormone-suppressing drug that has long been the standard approach. Both groups then moved on to additional cancer treatment before surgery. When researchers biopsied the tumors afterward, they found a meaningful difference in how aggressively each drug had worked.
The measure they used was a protein called Ki67, which cancer cells produce when they divide. More division means faster growth and greater risk of spread. Patients treated with giredestrant showed an 80 percent drop in Ki67 levels. Those given anastrozole saw a 67 percent reduction. That 13-point gap may sound modest on paper, but in oncology it signals something potentially significant: a drug that suppresses the machinery of cell division more effectively than what doctors have been using.
Giredestrant belongs to a new class of medications called selective estrogen receptor degraders. Unlike most existing hormone therapies, which require injection, giredestrant comes as a pill. The drugs work by blocking the cells that pull estrogen toward breast tumors, starving them of the hormone they need to grow. Earlier research suggests they may be especially valuable for women whose cancers have metastasized—spread beyond the breast—and become resistant to conventional treatments.
The scale of the potential impact is substantial. More than two-thirds of all breast cancers diagnosed in the United States are estrogen-receptor positive. The American Cancer Society estimates that nearly 200,000 women are diagnosed with this subtype annually. Of those, roughly half will eventually develop tumors that no longer respond to available therapies. For those women, a more potent option could mean the difference between disease progression and remission.
Dr. Sara Hurvitz, who co-authored the study and directs the Breast Cancer Clinical Research Program at UCLA's Jonsson Comprehensive Cancer Center, emphasized that the early signal is encouraging. Research from other studies has shown that when a tumor's Ki67 drops sharply after just two weeks of hormone therapy, patients tend to have better long-term outcomes and lower rates of recurrence. That connection suggests giredestrant's stronger initial effect could translate into real survival benefit, though that remains to be proven.
The next step is clear: larger, randomized trials will test whether this early promise holds up in broader populations and whether it truly reduces the chance that cancer will return. Hurvitz called the current data "solid rationale" for moving forward with those studies in both early-stage and advanced disease settings. For the women who will enroll in those trials, and for the thousands more waiting to see whether a new option emerges, the results represent a small but genuine shift in the landscape of available treatments.
Citas Notables
Our results provide an early indication that giredestrant may reduce cancer cell division to a greater extent than our standard of care treatment— Dr. Sara Hurvitz, director of the Breast Cancer Clinical Research Program at UCLA Jonsson Comprehensive Cancer Center
When a tumor drops its Ki67 after two weeks of anti-hormonal therapy, the patient has a lower chance of disease recurrence long-term— Dr. Sara Hurvitz
La Conversación del Hearth Otra perspectiva de la historia
Why does it matter that one drug drops Ki67 by 80 percent instead of 67 percent? That's a real number, but does it actually change how patients fare?
That's the right question. We don't know yet—not for certain. But there's a pattern in cancer research: when a tumor responds quickly and strongly to hormone therapy in those first two weeks, it's often a sign the patient will do better years down the line. The 13-point difference here is the kind of signal that makes researchers think giredestrant might be worth pursuing.
So this study is really a proof-of-concept, not proof that the drug works.
Exactly. It's a small, short study—191 women, two weeks of treatment. It shows the drug does what it's supposed to do better than the alternative. But whether that translates to women living longer or staying cancer-free longer? That's what the bigger trials will answer.
Who benefits most from a drug like this? Is it everyone with this type of cancer, or a specific group?
Right now, the real need is for women whose cancers have become resistant to standard therapy. About half of the 200,000 women diagnosed each year with this subtype will eventually hit that wall. For them, a new option that works differently could be genuinely life-changing.
And the pill form—why does that matter?
Convenience and quality of life. Most existing hormone therapies require injections. A pill you take at home is easier to stick with, and patients are more likely to take their medications consistently when they're not dealing with needles and clinic visits.
What's the timeline before women could actually access this drug if the trials go well?
That depends on how the larger studies perform and how quickly regulators move. These things typically take years. But the fact that researchers are already planning those next trials suggests there's real confidence in what they're seeing.